247 related articles for article (PubMed ID: 8866656)
21. Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice.
Sirova M; Strohalm J; Subr V; Plocova D; Rossmann P; Mrkvan T; Ulbrich K; Rihova B
Cancer Immunol Immunother; 2007 Jan; 56(1):35-47. PubMed ID: 16636810
[TBL] [Abstract][Full Text] [Related]
22. Polymeric conjugates of mono- and bi-cyclic alphaVbeta3 binding peptides for tumor targeting.
Mitra A; Coleman T; Borgman M; Nan A; Ghandehari H; Line BR
J Control Release; 2006 Aug; 114(2):175-83. PubMed ID: 16889865
[TBL] [Abstract][Full Text] [Related]
23. Polyacetal-doxorubicin conjugates designed for pH-dependent degradation.
Tomlinson R; Heller J; Brocchini S; Duncan R
Bioconjug Chem; 2003; 14(6):1096-106. PubMed ID: 14624622
[TBL] [Abstract][Full Text] [Related]
24. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties.
Etrych T; Jelínková M; Ríhová B; Ulbrich K
J Control Release; 2001 May; 73(1):89-102. PubMed ID: 11337062
[TBL] [Abstract][Full Text] [Related]
25. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 3. The effect of free and polymer-bound adriamycin on the expression of some genes in the OVCAR-3 human ovarian carcinoma cell line.
Kunath K; Kopecková P; Minko T; Kopecek J
Eur J Pharm Biopharm; 2000 Jan; 49(1):11-5. PubMed ID: 10613922
[TBL] [Abstract][Full Text] [Related]
26. New HPMA copolymer-based drug carriers with covalently bound hydrophobic substituents for solid tumour targeting.
Chytil P; Etrych T; Konák C; Sírová M; Mrkvan T; Boucek J; Ríhová B; Ulbrich K
J Control Release; 2008 Apr; 127(2):121-30. PubMed ID: 18304673
[TBL] [Abstract][Full Text] [Related]
27. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 1. influence of the method of synthesis on the binding affinity to OVCAR-3 ovarian carcinoma cells in vitro.
Omelyanenko V; Kopecková P; Gentry C; Shiah JG; Kopecek J
J Drug Target; 1996; 3(5):357-73. PubMed ID: 8866655
[TBL] [Abstract][Full Text] [Related]
28. Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic.
Duncan R; Gac-Breton S; Keane R; Musila R; Sat YN; Satchi R; Searle F
J Control Release; 2001 Jul; 74(1-3):135-46. PubMed ID: 11489490
[TBL] [Abstract][Full Text] [Related]
29. Combination chemotherapy and photodynamic therapy of targetable N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin/mesochlorin e(6)-OV-TL 16 antibody immunoconjugates.
Shiah JG; Sun Y; Kopecková P; Peterson CM; Straight RC; Kopecek J
J Control Release; 2001 Jul; 74(1-3):249-53. PubMed ID: 11489502
[TBL] [Abstract][Full Text] [Related]
30. Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin.
Talelli M; Iman M; Varkouhi AK; Rijcken CJ; Schiffelers RM; Etrych T; Ulbrich K; van Nostrum CF; Lammers T; Storm G; Hennink WE
Biomaterials; 2010 Oct; 31(30):7797-804. PubMed ID: 20673684
[TBL] [Abstract][Full Text] [Related]
31. Long-term biodistribution study of HPMA-ran-LMA copolymers in vivo by means of
Wagener K; Moderegger D; Allmeroth M; Reibel A; Kramer S; Biesalski B; Bausbacher N; Zentel R; Thews O; Rösch F
Nucl Med Biol; 2018 Mar; 58():59-66. PubMed ID: 29413458
[TBL] [Abstract][Full Text] [Related]
32. Synthetic macromolecular drug carriers: biodistribution of poly[(N-2-hydroxypropyl)methacrylamide] copolymers and their accumulation in solid rat tumors.
Kissel M; Peschke P; Subr V; Ulbrich K; Schuhmacher J; Debus J; Friedrich E
PDA J Pharm Sci Technol; 2001; 55(3):191-201. PubMed ID: 11417110
[TBL] [Abstract][Full Text] [Related]
33. HPMA copolymer-1,5-diazaanthraquinone conjugates as novel anticancer therapeutics.
Vicent MJ; Manzanaro S; de la Fuente JA; Duncan R
J Drug Target; 2004; 12(8):503-15. PubMed ID: 15621676
[TBL] [Abstract][Full Text] [Related]
34. FRET-trackable biodegradable HPMA copolymer-epirubicin conjugates for ovarian carcinoma therapy.
Yang J; Zhang R; Radford DC; Kopeček J
J Control Release; 2015 Nov; 218():36-44. PubMed ID: 26410808
[TBL] [Abstract][Full Text] [Related]
35. Biodistribution in tumour-bearing mice of polycationic, amphoteric and polyanionic branched polypeptides with a poly(L-lysine) backbone labelled with 125I and 111In: tumour accumulation less than that of labelled serum proteins.
Pimm MV; Hudecz F
J Cancer Res Clin Oncol; 1996; 122(1):45-54. PubMed ID: 8543592
[TBL] [Abstract][Full Text] [Related]
36. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470.
Satchi-Fainaro R; Puder M; Davies JW; Tran HT; Sampson DA; Greene AK; Corfas G; Folkman J
Nat Med; 2004 Mar; 10(3):255-61. PubMed ID: 14981512
[TBL] [Abstract][Full Text] [Related]
37. Polymer-bound camptothecin: initial biodistribution and antitumour activity studies.
Caiolfa VR; Zamai M; Fiorino A; Frigerio E; Pellizzoni C; d'Argy R; Ghiglieri A; Castelli MG; Farao M; Pesenti E; Gigli M; Angelucci F; Suarato A
J Control Release; 2000 Mar; 65(1-2):105-19. PubMed ID: 10699275
[TBL] [Abstract][Full Text] [Related]
38. HPMA copolymer-bound doxorubicin targeted to tumor-specific antigen of BCL1 mouse B cell leukemia.
Kovár M; Mrkvan T; Strohalm J; Etrych T; Ulbrich K; Stastný M; Ríhová B
J Control Release; 2003 Oct; 92(3):315-30. PubMed ID: 14568412
[TBL] [Abstract][Full Text] [Related]
39. Enhanced circulation time and antitumor activity of doxorubicin by comblike polymer-incorporated liposomes.
Han HD; Lee A; Hwang T; Song CK; Seong H; Hyun J; Shin BC
J Control Release; 2007 Jul; 120(3):161-8. PubMed ID: 17524514
[TBL] [Abstract][Full Text] [Related]
40. Biodistribution of doxorubicin-alkylated poly(L-lysine citramide imide) conjugates in an experimental model of peritoneal carcinomatosis after intraperitoneal administration.
Colombo PE; Boustta M; Poujol S; Pinguet F; Rouanet P; Bressolle F; Vert M
Eur J Pharm Sci; 2007 May; 31(1):43-52. PubMed ID: 17383164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
